Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A phase 2 study of 5 years of adjuvant imatinib in patients with gastrointestinal stromal tumor with a high risk of recurrence following surgical resection
KCT0007371Phase 2Recruiting
- Sponsor
- HK inno.N Corporation
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by HK inno.N Corporation. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on KCT0007371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007371.